Dose-dependent, therapeutic potential of angiotensin-(1–7) for the treatment of pulmonary arterial hypertension

Pulmonary Circulation

Volumn 5, Issue 4, 2015, Pages 649-657

  Breitling, Siegfried ^a,b   Krauszman, Adrienn ^a,c   Parihar, Richa ^a   Walther, Thomas ^d   Friedberg, Mark K ^e   Kuebler, Wolfgang M ^a,c,f,g  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b FREIE UNIVERSITÄT BERLIN   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d UNIVERSITY COLLEGE CORK   (Ireland)

^e HOSPITAL FOR SICK CHILDREN   (Canada)

^f UNIVERSITY OF TORONTO   (Canada)

^g DEUTSCHES HERZZENTRUM BERLIN   (Germany)

Author keywords

Pulmonary hypertension; Renin angiotensin system; Vascular remodeling

Indexed keywords

EID: 85026335988     PISSN: 20458932     EISSN: 20458940     Source Type: Journal    
DOI: 10.1086/683696     Document Type: Article

References (35)

1. Simonneau G, Robbins IM, Beghetti M, Channick RN, Delcroix M, Denton CP, Elliott CG, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009;54(1 Suppl):S43–S54.
2. Galiè N, Manes A, Branzi A. The endothelin system in pulmonary arterial hypertension. Cardiovasc Res 2004;61(2):227–337.
3. Hampl V, Herget J. Role of nitric oxide in the pathogenesis of chronic pulmonary hypertension. Physiol Rev 2000;80(4):1337–1372.
4. Rhodes CJ, Davidson A, Gibbs JSR, Wharton J, Wilkins MR. Therapeutic targets in pulmonary arterial hypertension. Pharmacol Ther 2009;121(1):69–88.
5. Thenappan T, Shah SJ, Rich S, Tian L, Archer SL, Gomberg-Maitland M. Survival in pulmonary arterial hypertension: a reappraisal of the NIH risk stratification equation. Eur Respir J 2010;35(5):1079–1087.
6. Bader M, Santos RA, Unger T, Steckelings UM. New therapeutic pathways in the RAS. J Renin Angiotensin Aldosterone Syst 2012;13(4): 505–508.
7. Farag E, Maheshwari K, Morgan J, Esa WAS, Doyle DJ. An update of the role of renin angiotensin in cardiovascular homeostasis. Anesth Analg 2015;120(2):275–292.
8. Ferreira AJ, Shenoy V, Yamazato Y, Sriramula S, Francis J, Yuan L, Castellano RK, et al. Evidence for angiotensin-converting enzyme 2 as a therapeutic target for the prevention of pulmonary hypertension. Am J Respir Crit Care Med 2009;179(11):1048–1054.
9. Santos RA, Simoes e Silva AC, Maric C, Silva DM, Machado RP, de Buhr I, Heringer-Walther S, et al. Angiotensin-(1–7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc Natl Acad Sci USA 2003;100(14):8258–8263.
10. Sampaio WO, Santos RA, Faria-Silva R, da Mata Machado LT, Schiffrin EL, Touyz RM. Angiotensin-(1–7) through receptor Mas mediates endothelial nitric oxide synthase activation via Akt-dependent pathways. Hypertension 2007;49(1):185–192.
11. Heitsch H, Brovkovych S, Malinski T, Wiemer G. Angiotensin-(1–7)- stimulated nitric oxide and superoxide release from endothelial cells. Hypertension 2001;37(1):72–76.
12. Grobe JL, Mecca AP, Lingis M, Shenoy V, Bolton TA, Machado JM, Speth RC, Raizada MK, Katovich MJ. Prevention of angiotensin IIinduced cardiac remodeling by angiotensin-(1–7). Am J Physiol Heart Circ Physiol 2007;292(2):H736–H742.
13. Zhang F, Hu Y, Xu Q, Ye S. Different effects of angiotensin II and angiotensin-(1–7) on vascular smooth muscle cell proliferation and migration. PLoS ONE 2010;5(8):e12323. doi:10.1371/journal.pone.0012323.
14. Tallant EA, Diz DI, Ferrario CM. Antiproliferative actions of angiotensin- (1–7) in vascular smooth muscle. Hypertension 1999; 34(4):950–957.
15. Chen L, Xiao J, Li Y, Ma H. Ang-(1–7) might prevent the development of monocrotaline induced pulmonary arterial hypertension in rats. Eur Rev Med Pharmacol Sci 2011;15(1):1–7.
16. Shenoy V, Ferreira AJ, Qi Y, Fraga-Silva RA, Díez-Freire C, Dooies A, Jun JY, et al. The angiotensin-converting enzyme 2/angiogenesis-(1–7)/ Mas axis confers cardiopulmonary protection against lung fibrosis and pulmonary hypertension. Am J Respir Crit Care Med 2010;182(8):1065–1072.
17. Yamada K, Iyer SN, Chappell MC, Ganten D, Ferrario CM. Converting enzyme determines plasma clearance of angiotensin-(1–7). Hypertension 1998;32(3):496–502.
18. Durik M, van Veghel R, Kuipers A, Rink R, Haas Jimoh Akanbi M, Moll G, Danser AH, Roks AJ. The effect of the thioether-bridged, stabilized angiotensin-(1–7) analogue cyclic Ang-(1–7) on cardiac remodeling and endothelial function in rats with myocardial infarction. Int J Hypertens 2012;2012:536426. doi:10.1155/2012/536426.
19. Yin N, Kaestle S, Yin J, Hentschel T, Pries AR, Kuppe H, Kuebler WM. Inhaled nitric oxide versus aerosolized iloprost for the treatment of pulmonary hypertension with left heart disease. Crit Care Med 2009;37(3):980–986.
20. Bueltmann M, Kong X, Mertens M, Yin N, Yin J, Liu Z, Koster A, Kuppe H, Kuebler WM. Inhaled milrinone attenuates experimental acute lung injury. Intensive Care Med 2009;35(1):171–178.
21. Hoffmann J, Yin J, Kukucka M, Yin N, Saarikko I, Sterner-Kock A, Fujii H, et al. Mast cells promote lung vascular remodelling in pulmonary hypertension. Eur Respir J 2011;37(6):1400–1410.
22. Galiè N, Badesch D, Oudiz R, Simonneau G, McGoon MD, Keogh AM, Frost AE, et al. Ambrisentan therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2005;46(3):529–535.
23. Haga S, Tsuchiya H, Hirai T, Hamano T, Mimori A. A novel ACE2 activator reduces monocrotaline-induced pulmonary hypertension by suppressing the JAK/STAT and TGF-β cascades with restored caveolin-1 expression. Exp Lung Res 2015;41(1):21–31.
24. US Food and Drug Administration. FDA approves new orphan drug for treatment of pulmonary arterial hypertension. http://web.archive.org/web/20070623055608/ http://www.fda.gov/bbs/topics/NEWS/2007/NEW01653.html. Published June 15, 2007. Accessed January 29, 2015.
25. Galiè N, Olschewski H, Oudiz RJ, Torres F, Frost A, Ghofrani HA, Badesch DB, et al. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation 2008;117(23):3010–3019.
26. Nishida M, Okada Y, Akiyoshi K, Eshiro K, Takoaka M, Gariepy CE, Yanagisawa M, Matsumura Y. Role of endothelin ETB receptor in the pathogenesis of monocrotaline-induced pulmonary hypertension in rats. Eur J Pharmacol 2004; 496 (1–3):159–165.
27. Abe K, Toba M, Alzoubi A, Ito M, Fagan KA, Cool CD, Voelkel NF, McMurtry IF, Oka M. Formation of plexiform lesions in experimental severe pulmonary arterial hypertension. Circulation 2010;121(25):2747–2754.
28. Gaddam RR, Chambers S, Bhatia M. ACE and ACE2 in inflammation: a tale of two enzymes. Inflam Allergy Drug Targets 2014;13(4):224–234.
29. Simões E, Silva AC, Silveira KD, Ferreira AJ, Teixeira MM. ACE2, angiotensin-(1–7) and Mas receptor axis in inflammation and fibrosis. Br J Pharmacol 2013;169(3):477–492.
30. de Vries L, Reitzema-Klein CE, Meter-Arkema A, van Dam A, Rink R, Moll GN, Haas Jimoh Akanbi M. Oral and pulmonary delivery of thioether-bridged angiotensin-(1–7). Peptides 2010;31(5):893–898.
31. Magalhães GS, Rodrigues-Machado MG, Motta-Santos D, Silva AR, Caliari MV, Prata LO, Abreu SC, et al. Angiotensin-(1–7) attenuates airway remodeling and hyperresponsiveness in a model of chronic allergic lung inflammation. Br J Pharmacol 2015;172(9):2330–2342.
32. El-Hashim AZ, Renno WM, Raghupathy R, Abduo HT, Akhtar S, Benter IF. Angiotensin-(1–7) inhibits allergic inflammation, via the MAS1 receptor, through suppression of ERK1/2- and NF-κB-dependent pathways. Br J Pharmacol 2012;166(6):1964–1976.
33. Benter IF, Yousif MHM, Cojocel C, Al-Maghrebi M, Diz DI. Angiotensin- (1–7) prevents diabetes-induced cardiovascular dysfunction. Am J Physiol Heart Circ Physiol 2007;292(1):H666–H672.
34. Kluskens LD, Nelemans SA, Rink R, de Vries L, Meter-Arkema A, Wang Y, Walther T, Kuipers A, Moll GN, Haas M. Angiotensin-(1–7) with thioether bridge: an angiotensin-converting enzyme-resistant, potent angiotensin-(1–7) analog. J Pharmacol Exp Ther 2009;328(3):849–854.
35. Yousif MH, Makki B, El-Hashim AZ, Akhtar S, Benter IF. Chronic treatment with Ang-(1–7) reverses abnormal reactivity in the corpus cavernosum and normalizes diabetes-induced changes in the protein levels of ACE, ACE2, ROCK1, ROCK2 and omega-hydroxylase in a rat model of type 1 diabetes. J Diabetes Res 2014;2014:142154. doi:10.1155/2014/142154.